ALNYLAM PHARMACEUTICALS, INC. Revenue
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Revenue of $1.29 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.29B, a 66.86% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.10B, a 84.95% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.25B, a 149.35% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $773.69M, a 17.26% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $3.71B, a 65.19% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $2.25B, a 22.97% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.83B, a 76.23% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.04B, a 22.88% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.29B 10-Q · filed 2026-07-30 | $2.46B 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $1.10B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $2.35B derived: sum of 2 quarters · filed 2026-02-12 | $3.12B derived: sum of 3 quarters · filed 2026-07-30 | $3.71B 10-K · filed 2026-02-12 | |
| 2025-09-30 | $1.25B 10-Q · filed 2025-10-30 | $2.02B derived: sum of 2 quarters · filed 2026-07-30 | $2.62B 10-Q · filed 2025-10-30 | $3.21B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $773.69M 10-Q · filed 2026-07-30 | $1.37B 10-Q · filed 2026-07-30 | $1.96B derived: sum of 3 quarters · filed 2026-07-30 | $2.46B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $594.19M 10-Q · filed 2025-05-01 | $1.19B derived: sum of 2 quarters · filed 2026-02-12 | $1.69B derived: sum of 3 quarters · filed 2026-02-12 | $2.35B derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | $593.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.09B derived: sum of 2 quarters · filed 2026-02-12 | $1.75B derived: sum of 3 quarters · filed 2026-02-12 | $2.25B 10-K · filed 2026-02-12 | |
| 2024-09-30 | $500.92M 10-Q · filed 2025-10-30 | $1.16B derived: sum of 2 quarters · filed 2025-10-30 | $1.66B 10-Q · filed 2025-10-30 | $2.09B derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-06-30 | $659.83M 10-Q · filed 2025-07-31 | $1.15B 10-Q · filed 2025-07-31 | $1.59B derived: sum of 3 quarters · filed 2026-02-12 | $2.34B derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-03-31 | $494.33M 10-Q · filed 2025-05-01 | $934.05M derived: sum of 2 quarters · filed 2026-02-12 | $1.68B derived: sum of 3 quarters · filed 2026-02-12 | $2.00B derived: sum of 4 quarters · filed 2026-02-12 | |
| 2023-12-31 | $439.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.19B derived: sum of 2 quarters · filed 2026-02-12 | $1.51B derived: sum of 3 quarters · filed 2026-02-12 | $1.83B 10-K · filed 2026-02-12 | |
| 2023-09-30 | $750.53M 10-Q · filed 2024-10-31 | $1.07B derived: sum of 2 quarters · filed 2024-10-31 | $1.39B 10-Q · filed 2024-10-31 | $1.72B derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-06-30 | $318.75M 10-Q · filed 2024-08-01 | $638.04M 10-Q · filed 2024-08-01 | $973.08M derived: sum of 3 quarters · filed 2025-02-13 | $1.24B derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-03-31 | $319.29M 10-Q · filed 2024-05-02 | $654.33M derived: sum of 2 quarters · filed 2025-02-13 | $918.63M derived: sum of 3 quarters · filed 2025-02-13 | $1.14B derived: sum of 4 quarters · filed 2025-02-13 | |
| 2022-12-31 | $335.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $599.34M derived: sum of 2 quarters · filed 2025-02-13 | $824.16M derived: sum of 3 quarters · filed 2025-02-13 | $1.04B 10-K · filed 2025-02-13 | |
| 2022-09-30 | $264.31M 10-Q · filed 2023-11-02 | $489.12M derived: sum of 2 quarters · filed 2023-11-02 | $702.38M 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $224.82M 10-Q · filed 2023-08-03 | $438.08M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $213.26M 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | $844.29M 10-K · filed 2024-02-15 | ||||
| 2021-06-30 | $220.55M 10-Q · filed 2021-08-03 | $398.12M 10-Q · filed 2021-08-03 | $561.68M derived: sum of 3 quarters · filed 2021-08-03 | $687.53M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2021-03-31 | $177.57M 10-Q · filed 2021-04-29 | $341.13M derived: sum of 2 quarters · filed 2021-04-29 | $466.98M derived: sum of 3 quarters · filed 2021-04-29 | $570.94M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-12-31 | $163.56M 10-K · filed 2021-02-11 | $289.42M derived: sum of 2 quarters · filed 2021-02-11 | $393.38M derived: sum of 3 quarters · filed 2021-08-03 | $492.85M 10-K · filed 2021-02-11 | |
| 2020-09-30 | $125.85M 10-K · filed 2021-02-11 | $229.81M derived: sum of 2 quarters · filed 2021-08-03 | $329.29M 10-Q · filed 2020-11-05 | $400.97M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-06-30 | $103.96M 10-Q · filed 2021-08-03 | $203.44M 10-Q · filed 2021-08-03 | $275.12M derived: sum of 3 quarters · filed 2021-08-03 | $345.18M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-03-31 | $99.48M 10-Q · filed 2021-04-29 | $171.16M derived: sum of 2 quarters · filed 2021-04-29 | $241.22M derived: sum of 3 quarters · filed 2021-04-29 | $285.93M derived: sum of 4 quarters · filed 2021-04-29 | |
| 2019-12-31 | $71.68M 10-K · filed 2021-02-11 | $141.74M derived: sum of 2 quarters · filed 2021-02-11 | $186.46M derived: sum of 3 quarters · filed 2021-02-11 | $219.75M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $70.06M 10-K · filed 2021-02-11 | $114.78M derived: sum of 2 quarters · filed 2021-02-11 | $148.07M 10-Q · filed 2020-11-05 | $169.10M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-06-30 | $44.71M 10-K · filed 2021-02-11 | $78.01M 10-Q · filed 2020-08-06 | $99.04M derived: sum of 3 quarters · filed 2021-02-11 | $101.11M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-03-31 | $33.29M 10-K · filed 2021-02-11 | $54.33M derived: sum of 2 quarters · filed 2021-02-11 | $56.40M derived: sum of 3 quarters · filed 2021-02-11 | $86.30M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2018-12-31 | $21.03M 10-K · filed 2020-02-13 | $23.10M derived: sum of 2 quarters · filed 2020-02-13 | $53.01M derived: sum of 3 quarters · filed 2020-02-13 | $74.91M 10-K · filed 2021-02-11 | |
| 2018-09-30 | $2.07M 10-K · filed 2020-02-13 | $31.98M derived: sum of 2 quarters · filed 2020-02-13 | $53.88M 10-Q · filed 2019-10-31 | $91.80M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-06-30 | $29.91M 10-K · filed 2020-02-13 | $51.81M 10-Q · filed 2019-08-06 | $89.73M derived: sum of 3 quarters · filed 2020-02-13 | $106.83M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-03-31 | $21.90M 10-K · filed 2020-02-13 | $59.82M derived: sum of 2 quarters · filed 2020-02-13 | $76.92M derived: sum of 3 quarters · filed 2020-02-13 | $92.85M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-01-01 | $2.90M 10-K · filed 2021-02-11 | ||||
| 2017-12-31 | $37.92M 10-K · filed 2019-02-14 | $55.02M derived: sum of 2 quarters · filed 2019-02-14 | $70.95M derived: sum of 3 quarters · filed 2019-02-14 | $89.91M 10-K · filed 2020-02-13 | |
| 2017-09-30 | $17.10M 10-K · filed 2019-02-14 | $33.03M derived: sum of 2 quarters · filed 2019-02-14 | $51.99M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $15.93M 10-K · filed 2019-02-14 | $34.89M 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | $18.96M 10-K · filed 2019-02-14 | ||||
| 2016-12-31 | $47.16M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |